Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Proactively manage your pharmacy inventory
Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
Manage your formulary budget
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Method of treating leukemia or leukemoid diseases|
|Abstract:||A method of leukemia or leukemoid disease treatment by administration of a vitamin D derivative with a hydroxyl group at 1.alpha.-position is disclosed. It is believed that the vitamin D derivative with a hydroxyl group at 1.alpha.-position is capable of treating cancer through redifferentiation of cancer cells and that this capability is inherent in vitamin D derivatives with a hydroxyl group at 1.alpha.-position.|
|Inventor(s):||Suda; Tatsuo (Tachikawa, JP), Hirasawa; Yoshihei (Niigata, JP), Takahashi; Sachio (Niigata, JP), Abe; Etsuko (Tokyo, JP), Konno; Kunio (Tokyo, JP), Aoki; Tadao (Niigata, JP)|
|Assignee:||Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP)|
Patent Claim Types:|
see list of patent claims
|Use; Dosage form;|
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|Japan||56-35218||Mar 13, 1981|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.